[1] Choi Y J, Kim H K, Lee S C, et al. Validation of the hypertrophic cardiomyopathy risk-sudden cardiac death calculator in the Asians[J]. Heart, 2019, doi:10.1136/heartjnl-2019-315694. [2] Inciardi R M, Galderisi M, Nistri S, et al. Echocardiographic advances in hypertrophic cardiomyopathy:Three-dimensional and strain imaging echocardiography[J]. Echocardiography, 2018,12(7):59-64. [3] Chen R, Ge T, Jiang W, et al. Identification of biomarkers correlated with hypertrophic cardiomyopathy with co-expression analysis[J]. Journal of Cellular Physiology, 2019,234(7):39-45. [4] Cochet H, Dubois R, Yamashita S, et al. Relationship between fibrosis detected on late gadolinium-enhanced cardiac magnetic resonance and re-entrant activity assessed with electrocardiographic imaging in human persistent atrial fibrillation[J]. Journal of the American College of Cardiology, 2018,4(1):17-29. [5] Vita T, Okada D R, Veilletchowdhury M, et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis[J]. Circulation-Cardiovascular Imaging, 2018,16(7):59-64. [6] Chubb H, Karim R, Sébastien R, et al. The reproducibility of late gadolinium enhancement cardiovascular magnetic resonance imaging of post-ablation atrial scar:a cross-over study[J]. Journal of Cardiovascular Magnetic Resonance, 2018,20(1):21-25. [7] Higuchi K, Cates J, Gardner G, et al. The spatial distribution of late gadolinium enhancement of left atrial magnetic resonance imaging in patients with atrial fibrillation[J]. Journal of the American College of Cardiology, 2018,4(1):49-53. [8] Ammirati E, Sormani P, Moroni F, et al. Changes of late gadolinium enhancement extension compared with native T1 mapping early after acute myocarditis[J]. International Journal of Cardiology, 2018,25(5):27-34. [9] Yanagisawa F, Amano Y, Tachi M, et al. Non-contrast-enhanced T1 mapping of dilated cardiomyopathy:comparison between native T1 values and late gadolinium enhancement[J]. Magnetic Resonance in Medical Sciences, 2018,18(1):18-25. [10] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会, 中国心肌病诊断与治疗建议工作组.心肌病诊断与治疗建议[J].中华心血管病杂志, 2007,35(1):5-16. [11] Kitano T, Matsubara S, Uno M, et al. Vessel wall enhancement by gadolinium-enhanced MRI in a patient with delayed stenosis after mechanical thrombectomy[J]. BMJ Case Reports, 2018,18(5):37-45. [12] Mathur S, Dreisbach J G, Karur G R, et al. Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in fabry disease:relationship to T1 mapping, late gadolinium enhancement and hypertrophy[J]. Journal of Cardiovascular Magnetic Resonance, 2019,21(1):45-53. [13] Li J, Cui Y, Huang A, et al. Additional diagnostic value of growth differentiation factor-15(GDF-15) to N-terminal B-type natriuretic peptide (NT-proBNP) in patients with different stages of heart failure[J]. Medical Science Monitor, 2018,24:4992-4999. [14] Chen C Y J, Yang T C, Chang C, et al. Homocysteine is a bystander for ST-segment elevation myocardial infarction:a case-control study[J]. BMC Cardiovascular Disorders, 2018,18(1):689-693. [15] 杜永海, 霍玉峰. TenascinC、H-FABP、NT-proBNP的变化与瓣膜性心脏病心力衰竭患者心功能变化的关系[J].河北医药, 2020,42(19):2975-2977. [16] Kate L, Anna B, Alberto P, et al.Cardiovascular magnetic resonance of myocardial fibrosis, edema, and infiltrates in heart failure[J]. Heart Failure Clinics, 2021,17(1):77-84. [17] Custodero C, Wu Q, Ghita G L, et al. Prognostic value of NT-proBNP levels in the acute phase of sepsis on lower long-term physical function and muscle strength in sepsis survivors[J]. Critical Care, 2019,23(1):69-74. [18] 方斌, 王东武, 王海龙, 等. 心脉隆注射液联合曲美他嗪对冠心病并CHF患者血NT-proBNP、cTnI TGF-β1、GDF-15水平的影响观察[J]. 哈尔滨医药, 2019,39(1):1-2. |